Pertuzumab, Trastuzumab, is a targeted therapy containing the active constituents pertuzumab and trastuzumab. These were approved by the U.S. Food and Drug Administration (FDA) for treating HER2-positive breast cancer in combination with chemotherapy on June 8, 2012. Cancer occurs when cells begin to grow abnormally in an uncontrolled manner.

Pertuzumab, Trastuzumab, is used to treat breast cancer (human epidermal growth factor receptor 2 positive breast cancer) that has spread to other parts of the body (metastasized) or cancer that has come back after the treatment. It will also be given before or after the surgery if the cancer has not metastasized.

Pertuzumab, Trastuzumab is a medication administered intravenously (IV) by a healthcare professional. It is important to follow the healthcare provider's instructions regarding the dosage and administration of medication. Refrain from doubling the dose to make up for missed doses.

Pertuzumab, Trastuzumab can cause several side effects, both common and serious. The most common side effects include fatigue, diarrhea, nausea, vomiting, and decreased appetite. These side effects are often mild to moderate and can be managed with supportive care. However, these can also cause more serious side effects like heart-related complications, infusion-related reactions, and immune-related adverse events.

Pertuzumab, Trastuzumab carry important warnings, particularly regarding their potential to cause cardiac toxicity, which can lead to congestive heart failure, arrhythmias, and other cardiac complications. Other warnings include the potential to cause infusion-related reactions, lung toxicity, and fetal harm during pregnancy.

Patients with a history of severe hypersensitivity reactions or anaphylactic shock should not receive Pertuzumab, Trastuzumab. It is also not recommended for use in patients with autoimmune disorders or those who are immunocompromised. Patients with a history of cardiac events, liver or kidney disease, or pulmonary embolism should be closely monitored during treatment. Patients should discuss these risks and benefits with their healthcare provider before starting treatment with pertuzumab and trastuzumab.

If you are prescribed Pertuzumab, Trastuzumab, or any other medication, it is important to carefully read and understand the warnings and precautions associated with the medication. Patients should be monitored for signs of an allergic reaction, such as rash, itching, or swelling, and should seek immediate medical attention if these symptoms occur. It should be used with caution in patients with severe renal impairment. Talk to the physician if you have heart problems, have had radiotherapy, or have allergic conditions. Use effective birth control during the treatment and at least seven months after the last dose. Always maintain a healthy and balanced diet to support your overall health and well-being.

1. Roche products limited, Electronic medicines compendium (EMC), [Revised on Jan 2022] [ Accessed on 03/05/2023], https://www.medicines.org.uk/emc/files/pil.11989.pdf
2. zhu Chenjing et al.; Safety and efficacy evaluation of pertuzumab in patients with solid tumors; Medicine; [Published on May 2017]; [Accessed on 03/05/2023] https://journals.lww.com/md-journal/fulltext/2017/05190/safety_and_efficacy_evaluation_of_pertuzumab_in.19.aspx
3. Sandra M Swain et al; Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer; The New England Journal of Medicine; [Published on Feb 2015]; [Accessed on 03/05/203]; https://pubmed.ncbi.nlm.nih.gov/25693012/

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.